Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

Josep Tabernero; Axel Grothey; Eric Van Cutsem; Rona Yaeger; Harpreet Wasan; Takayuki Yoshino; Jayesh Desai; Fortunato Ciardiello; Fotios Loupakis; Yong Sang Hong; Neeltje Steeghs; Tormod Kyrre Guren; Hendrik-Tobias Arkenau; Pilar García‐Alfonso; Élena Elez; Ashwin Gollerkeri; Kati Maharry; Janna Christy‐Bittel; Scott Kopetz

doi:10.1200/jco.20.02088

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

In the BEACON CRC study, encorafenib plus cetuximab improved OS, ORR, and progression-free survival in previously treated patients in the metastatic setting compared with standard chemotherapy. Based on the primary and updated analyses, encorafenib plus cetuximab is a new standard care regimen for previously treated patients with BRAF V600E mCRC.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tabernero et al. (2021) studied this question.

synapsesocial.com/papers/69de9e1357c7c8340a558d5c https://doi.org/10.1200/jco.20.02088

View Full Paper

Ask AI

Bookmark

Share

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

Ask about this paper

Abstract

Discussion

Cite This Study

Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading